Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Opus Group in conjunction with issuance of bonds
Mandate

Vinge advises Opus Group in conjunction with issuance of bonds

May 28, 2018 Capital Markets and Public M&A

Opus Group AB (publ) (”Opus”) has issued a so called senior unsecured bond in the amount of MSEK 500 MSEK with a term of four years on the Nordic market.

The bond, with a framework amount of MSEK 800, is subject to a variable interest rate of STIBOR 3m + 375 interest points and has a final maturity date in May 2022. The proceeds from the bond issue will primarily be used for refinancing Opus’ outstanding bond in the amount of MSEK 500 with a final maturity date on 20 November 2018 (ISIN: SE0005556834). Opus will apply for listing of the bond on Nasdaq Stockholm.

Vinge’s team consisted of partner Anders Strid together with, among others, associates Yohanna Öhrnegård and Lina André.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026